PU-H71 inhibits tumor growth in MCL PDX models. (A) Tumor volume was measured weekly (length × width²  × 0.5) after animals were treated with control, PU-H71 (75 mg/kg, intraperitoneal injection), and ibrutinib (50 mg/kg, oral daily) on days 0, 7, 14, and 21 after treatment initiation. *P < .0001 (B) Survival curve analyzed with Graphpad Prism 6.0 software.